A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be developed. The investigators propose to investigate the effect of RANKL inhibition with denosumab on breast tissue markers in high-risk premenopausal women with dense breasts. Study findings could provide robust evidence to move forward with a clinical trial targeting RANKL inhibition in premenopausal breast cancer prevention.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Effect of denosumab on breast tissue gene pathway gene expression
Timeframe: Between baseline and day 60
Effect of denosumab on pathways that may influence breast cancer development as measured by spatial transcriptomic analysis
Timeframe: Between baseline and day 60
Effect of denosumab on pathways that may influence breast cancer development as measured by metabolomic analysis
Timeframe: Between baseline and day 60